SHANGHAI, China, March 25, 2020 (GLOBE NEWSWIRE) — Molecular Data Inc. (“Molecular Data” or the “Company”) (Nasdaq: MKD), a leading technology-driven platform in China’s chemical industry, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2019.
Fourth Quarter and Fiscal Year 2019 Financial HighlightsNet revenues in the fourth quarter of 2019 were RMB4,101.2 million (US$589.1 million), a 38.1% increase from RMB2,969.6 million in the fourth quarter of 2018. Net revenues in fiscal year 2019 were RMB13.2 billion (US$1,902.6 million), a 46.3% increase from RMB9.1 billion in fiscal year 2018.Gross profit in the fourth quarter of 2019 was RMB37.4 million (US$5.4 million), a 10.8% increase from RMB33.7 million in the fourth quarter of 2018. Gross profit in fiscal year 2019 was RMB103.0 million (US$14.8 million), a 28.5% increase from RMB80.2 million in fiscal year 2018.Net loss in the fourth quarter of 2019 was RMB58.1 million (US$8.3 million), compared with RMB166.6 million in the fourth quarter of 2018. Net loss in fiscal year 2019 was RMB191.3 million (US$27.5 million), compared with RMB254.6 million in fiscal year 2018.Fourth Quarter and Fiscal Year 2019 Operational UpdatesGMV1 under direct sales model in the fourth quarter of 2019 was RMB4,069.9 million, a 37.3% increase from RMB2,964.6 million in the fourth quarter of 2018. GMV under direct sales model in fiscal year 2019 was RMB13.2 billion, a 45.9% increase from RMB9.0 billion in fiscal year 2018.GMV under marketplace model in the fourth quarter of 2019 was RMB65.1 billion, a 63.6% increase from RMB39.8 billion in the fourth quarter of 2018. GMV under marketplace model in fiscal year 2019 was RMB241.9 billion, a 50.5% increase from RMB160.7 billion in fiscal year 2018.Total GMV under direct sales and marketplace models in the fourth quarter of 2019 was RMB69.2 billion (US$9.9 billion), a 61.7% increase from RMB42.8 billion in the fourth quarter of 2018. Total GMV under direct sales and marketplace models in fiscal year 2019 was RMB255.1 billion (US$36.4 billion), a 50.3% increase from RMB169.7 billion in fiscal year 2018.As of December 31, 2019, the Company had accumulated 11,745 customers and 6,253 suppliers on the Company’s online platform under direct sales model, compared with 9,007 customers and 5,163 suppliers as of December 31, 2018.As of December 31, 2019, the Company had accumulated 110,565 customers and 32,836 suppliers on the Company’s online platform under marketplace model, compared with 90,129 customers and 32,011 suppliers as of December 31, 2018.As of December 31, 2019, the Company had over 229,980 users and accumulated a total number of 116,291 customers and 35,456 suppliers on the Company’s online platform under direct sales and marketplace models, compared with 178,220 users, 94,373 customers and 33,752 suppliers as of December 31, 2018.______________
1 “GMV” refers to gross merchandise value of the transaction orders placed by customers under the direct sales model or the gross merchandise value of the transaction orders the Company facilitates between customers and suppliers under the marketplace model during the specified period; under the direct sales model, the GMV does not include discounts or returns by the customers and may include the shipping fees in some cases; under the marketplace model, the GMV does not include shipping fees or discounts, regardless of whether the chemicals are actually delivered or returned.Management Comments“2019 was a landmark year for us, highlighted by our IPO on the Nasdaq Stock Market, on December 30, 2019, which created immediate and increased brand awareness to new users, customers and partners,” said Dr. Dongliang Chang, Founder of the Company and Chairman of the Board. “We finished 2019 strong with a number of operational and financial achievements across the board. To continue our growth momentum in 2020, our strategies focus on expanding our user base, strengthening customer engagement and retention, as well as further observing and meeting our customers’ evolving and diverse needs along the entire chemical value chain.”“We are pleased to see solid progress with growth across each of our core business segments in 2019. It is worth noting that net revenues from our marketplace model and online membership service both achieved three-digit year-over-year growth,” commented Dr. Zheng Wang, Chief Executive Officer and Director of the Company. “With the increasing need of chemical industry participants to improve their operational efficiencies, the steady growth of the chemical industry, and an increasing internet penetration of the chemical e-commerce market, we believe our comprehensive and sophisticated chemical knowledge engine and business intelligence capabilities, our one-stop comprehensive suite of services, and our innovative big data and AI technologies, place us in an ideal position to further our leadership position in the sector. As we move through 2020, we will continue to invest in our knowledge engine and other technologies while looking forward to further growing our GMV, diversifying our value-added services and expanding global presence.“With respect to the COVID-19 pandemic, since its outbreak, many business operations in China were halted and factories were temporarily closed for a period of time, which would negatively affect our overall financial results in the first quarter of 2020. Depending on the global progression of the outbreak, our ability to obtain chemicals and deliver chemicals to customers may be partly or completely disrupted not only in our Chinese facilities but globally. However, at the same time, we observed increased online traffic on our platform in early 2020 during the outbreak, compared to the same period in 2019, especially from overseas customers and suppliers, which is also in line with our business strategy this year. We are also actively promoting our financial services to customers and suppliers on our platform to address potential financial needs during the outbreak. We believe that we can effectively cope with the dynamics caused by the outbreak and will continue to closely monitor the evolving situation,” Dr. Wang concluded.“We are pleased with our strong financial results for both the fourth quarter and fiscal year 2019, achieving outstanding revenue growth while narrowing net loss. Our balance sheet has also been maintained at a healthy level,” said Mr. Zhaohong Li, Chief Financial Officer of the Company. “With a goal to extend our solid growth trend in 2020, we look forward to further improving our results of operation with an emphasis on margin expansion and operational efficiencies improvement.”Fourth Quarter 2019 Financial ResultsNet RevenuesNet revenues were RMB4,101.2 million (US$589.1 million), a 38.1% increase from RMB2,969.6 million in the same period of 2018. The increase was primarily attributable to the steady increase in the number of users on the platform.Net revenues from direct sales model were RMB4,079.9 million (US$586.0 million), a 37.6% increase from RMB2,964.6 million in the same period of 2018.
Net revenues from marketplace model were RMB15.6 million (US$2.2 million), a 376.9% increase from RMB3.3 million in the same period of 2018.
Net revenues from online membership service were RMB3.7 million (US$0.5 million), a 113.2% increase from RMB1.8 million in the same period of 2018.
Net revenues from financial service were RMB0.5 million (US$0.07 million), compared with nil in the same period of 2018.Cost of RevenuesCost of revenues was RMB4,063.8 million (US$583.7 million), a 38.4% increase from RMB2,935.9 million in the same period of 2018. This change was primarily due to the increase in net revenues.Gross Profit and Gross MarginGross profit was RMB37.4 million (US$5.4 million), a 10.8% increase from RMB33.7 million in the same period of 2018. Gross margin decreased to 0.9%, compared with 1.1% in the same period of 2018. The decrease in gross margin was primarily due to a larger amount of basic chemicals that were procured by new users on the platform which have relatively lower gross margin.Operating ExpensesTotal operating expenses were RMB93.7 million (US$13.5 million), a 52.5% decrease from RMB197.5 million in the same period of 2018. The decrease was primarily due to the reduction of expenses associated with share-based compensation in the fourth quarter of 2019 compared to the same period in 2018.Sales and marketing expenses were RMB25.7 million (US$3.7 million), a 48.9% decrease from RMB50.3 million in the same period of 2018. This was primarily due to decreased share-based compensation for marketing personnel.
General and administrative expenses were RMB26.4 million (US$3.8 million), an 80.2% decrease from RMB133.1 million in the same period of 2018. This was primarily due to improved operational efficiencies and decreased share-based compensation for administrative personnel.
Research and development expenses were RMB14.5 million (US$2.1 million), a 15.3% decrease from RMB17.2 million in the same period of 2018. This was primarily due to decreased share-based compensation for R&D personnel.Operating LossOperating loss was RMB56.4 million (US$8.1 million), compared with RMB163.8 million in the same period of 2018.Net LossNet loss was RMB58.1 million (US$8.3 million), compared with RMB166.6 million in the same period of 2018.Fiscal Year 2019 Financial ResultsNet RevenuesNet revenues were RMB13.2 billion (US$1,902.6 million), a 46.3% increase from RMB9.1 billion in fiscal year 2018. The increase was primarily attributable to the Company’s efforts to diversify product offerings and an increase in overall GMV.Net revenues from direct sales model were RMB13.2 billion (US$1,897.0 million), a 46.0% increase from RMB9.0 billion in fiscal year 2018. The increase was primarily attributable to an increase in total number of users and customers, an increase in overall GMV, and the expansion of chemical product categories and value-added services.
Net revenues from marketplace model were RMB26.5 million (US$3.8 million), a 504.4% increase from RMB4.4 million in fiscal year 2018. The increase was primarily attributable to the increased customer engagement on the platform and the Company’s efforts to provide more value-added services to the customers.
Net revenues from online membership service were RMB10.7 million (US$1.5 million), a 211.3% increase from RMB3.4 million in fiscal year 2018. The increase was primarily attributable to the increased number of users signing up for the online membership services.
Net revenues from financial service were RMB0.9 million (US$0.1 million), compared with nil in fiscal year 2018, as the Company commenced monetizing on financial service in July 2019.Cost of RevenuesCost of revenues was RMB13.1 billion (US$1,887.8 million), a 46.5% increase from RMB9.0 billion in fiscal year 2018. This change was primarily due to the increase in the purchase volume of chemicals, which was in line with the net revenues growth.Gross Profit and Gross MarginGross profit was RMB103.0 million (US$14.8 million), a 28.5% increase from RMB80.2 million in fiscal year 2018. Gross margin decreased to 0.8%, compared with 0.9% in fiscal year 2018. The slight decrease in gross margin was primarily due to a larger amount of basic chemicals that were procured by new users on the platform which have relatively lower gross margin.Operating ExpensesTotal operating expenses were RMB293.0 million (US$42.1 million), a 7.3% decrease from RMB316.0 million in fiscal year 2018.Sales and marketing expenses were RMB108.9 million (US$15.6 million), a 5.4% increase from RMB103.3 million in fiscal year 2018.
General and administrative expenses were RMB104.5 million (US$15.0 million), a 39.9% decrease from RMB173.9 million in fiscal year 2018. This was primarily due to improved operational efficiencies and decreased share-based compensation for administrative personnel.
Research and development expenses were RMB45.0 million (US$6.5 million), a 22.1% increase from RMB36.9 million in fiscal year 2018. This was primarily due to the constant increase of R&D investments.Operating LossOperating loss was RMB190.0 million (US$27.3 million), compared with RMB235.8 million in fiscal year 2018.Net LossNet loss was RMB191.3 million (US$27.5 million), compared with RMB254.6 million in fiscal year 2018.Certain Balance Sheet ItemAs of December 31, 2019, the Company had cash, cash equivalents and restricted cash of RMB57.7 million (US$8.3 million), compared to RMB6.5 million as of December 31, 2018.Conference CallThe Company’s management will host an earnings conference call at 8:00 PM U.S. Eastern Time on March 25, 2020 (8:00 AM Beijing/Hong Kong time on March 26, 2020).Dial-in details for the earnings conference call are as follows:A telephone replay will be available two hours after the call until April 8, 2020 by dialing:Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://investor.molbase.com/.About Molecular Data Inc.Molecular Data Inc. is a leading technology-driven platform in China’s chemical industry, connecting participants along the chemical value chain through integrated solutions. The Company delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and SaaS suite that are intended to solve pain points for participants in the traditional chemical industry. Built upon a comprehensive knowledge engine and artificial intelligence (AI) capabilities, the Company’s e-commerce solutions are mainly offered through its online platform, consisting of molbase.com, molbase.cn, Moku Data Weixin account, Chemical Community App and other ancillary platforms.Exchange Rate InformationThis announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.9618 to US$1.00, the rate in effect as of December 31, 2019 published by the Federal Reserve Board.Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” “potential,” “continue” or other similar expressions. Among other things, the Outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a variety of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, results of operations and financial condition; the expected growth of the education market; the Company’s ability to monetize the user base; fluctuations in general economic and business conditions in China; the potential impact of the COVID-19 to the Company’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and the Company undertakes no duty to update such information, except as required under applicable law.For investor and media inquiries, please contact:In China:Molecular Data Inc.
E-mail: firstname.lastname@example.orgThe Piacente Group, Inc.
E-mail: email@example.comIn the United States:The Piacente Group, Inc.
E-mail: firstname.lastname@example.orgSource: Molbase
OMNIQ’s CEO Interviewed on “CEO Roadshow”
SALT LAKE CITY, April 01, 2020 (GLOBE NEWSWIRE) — OMNIQ Corp. (OMQS) (“OMNIQ” or “the Company”), a provider of Supply Chain and Artificial Intelligence (AI)-based solutions, today announced that its CEO, Shai Lustgarten, recently conducted an interview with Mike Elliott of CEO Roadshow.
The interview may be viewed in its entirety via: CEORoadshowhttp://ceoroadshow.com/ceoroadshow-interview-with-shai-lustgarten-president-ceo-of-omniq-corp-omqs/Interview Highlights:OMNIQ provides unique and scalable AI-Machine Vision technology solutions to the Public Safety, Supply Chain and Automated parking industriesCompany customer base comprised of Fortune 500 leading companies, governments, municipalities, schools and colleges, cultural and religious centers and others.Company participates in rapidly growing, multi-billion dollar market verticalsOMNIQ holds 8 patents and has developed algorithms applicable to:
– Vehicle comprehensive license plate, color and make recognition for use in homeland security, public safety and automated parking
– AI-based Machine Vision solutions for supply chain & logistics promoting efficiencies from warehouse/yard management through point of sale
– Comprehensive parking management solution enabling ticketless parking, automation and revenue control currently installed at more than 30 major airports in the U.S.Company in a unique position offering state-of-the-art, high margin technology solutionsAbout OMNIQ, Corp.
OMNIQ Corp. (OMQS) provides computerized and machine vision image processing solutions that use patented and proprietary AI technology to deliver data collection, real time surveillance and monitoring for supply chain management, homeland security, public safety, traffic & parking management and access control applications. The technology and services provided by the Company help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders, and many other applications and environments.
OMNIQ’s customers include government agencies and leading Fortune 500 companies from several sectors, including manufacturing, retail, distribution, food and beverage, transportation and logistics, healthcare, and oil, gas, and chemicals. Since 2014, annual revenues have grown to more than $50 million from clients in the USA and abroad.
The Company currently addresses several billion-dollar markets, including the Global Safe City market, forecast to grow to $29 billion by 2022, and the Ticketless Safe Parking market, forecast to grow to $5.2 billion by 2023. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. This release contains “forward-looking statements” that include information relating to future events and future financial and operating performance. The words “anticipate”, “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company’s products particularly during the current health crisis , the introduction of new products, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, the Company’s ability to manage credit and debt structures from vendors, debt holders and secured lenders, the Company’s ability to successfully integrate its acquisitions, and other information that may be detailed from time-to-time in OMNIQ Corp.’s filings with the United States Securities and Exchange Commission. Examples of such forward looking statements in this release include, among others, statements regarding revenue growth, driving sales, operational and financial initiatives, cost reduction and profitability, and simplification of operations. For a more detailed description of the risk factors and uncertainties affecting OMNIQ Corp., please refer to the Company’s recent Securities and Exchange Commission filings, which are available at http://www.sec.gov. OMNIQ Corp. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by law.Investor Contact:
John Nesbett/Jen Belodeau
IMS Investor Relations
Enterprise Connect Announces Winners for the Best of Enterprise Connect Industry Awards
SAN FRANCISCO, April 01, 2020 (GLOBE NEWSWIRE) — Enterprise Connect, the leading conference and exhibition for enterprise communications and collaboration, is pleased to announce the winners for The Best of Enterprise Connect awards program. Best of Enterprise Connect recognizes excellence and innovation in the enterprise communications and collaboration industry.
“We’d like to extend a congratulations to all of this year’s Best of Enterprise Connect winners and participants,” said Eric Krapf, Enterprise Connect General Manager and Program Co-Chair. “These companies represent the most innovative technologies that are making a significant impact on the enterprise communications and collaboration industry.”Recipients of The Best of Enterprise Connect Awards include:OVERALL Best of Enterprise Connect (Winner)JourneyJourney Identity Platform, which aims to make it easy for enterprises to establish trusted interactions with their customers that simultaneously solve for security, customer experience and privacy using an encrypted network and a platform of best-in-class identity solutions that can be dynamically applied using the enterprise’s existing mobile app.OVERALL Best of Enterprise Connect (Finalists)Genesys Predictive Engagement, now working within Genesys Cloud, new capabilities enable businesses to anticipate individual customer needs, building on every interaction across multiple channels and events to improve and personalize future engagements.Glia Conversational Compliance AI Framework, part of Glia’s digital-first customer service platform, provides the framework to provision, measure and manage AI-driven virtual assistants to converse with customers and operator assistants to guide agents.Mio’s new intercompany federation for Microsoft Teams, Slack and Cisco WebEx Teams enables users to chat seamlessly with external business contacts who use a different messaging app.Omilia Natural Language Solutions — Omilia Cloud Platform miniApps, zero-touch natural language microservices that handle a single dialog task; instantly deployable to any call center provider and seamlessly adapted to any CCaaS service creation environmentPexip, Adaptive Composition, an AI-powered technology with real-time face detection, auto-framing, and optimized use of screen real estate; works with any camera-enabled deviceBest Innovation for Meeting Rooms (Three-way tie)AvayaAvaya Spaces, a simple cloud solution that integrates friction-free web meetings and team collaboration into one app.Kramer ElectronicsVIA GO², which gives iOS, Android, Chromebook, PC and Mac users instant wireless connectivity with advanced presentation technology, featuring content streaming for 4K mirrored images and video playback.RingCentralFor a new product that will be announced at Enterprise Connect.Best Innovation in Customer ExperienceJourneyJourney Identity Platform, which aims to make it easy for enterprises to establish trusted interactions with their customers that simultaneously solve for security, customer experience and privacy using an encrypted network and a platform of best-in-class identity solutions that can be dynamically applied using the enterprise’s existing mobile app.Best Application of Artificial Intelligence (Three-way tie)GenesysGenesys Predictive Engagement, now working within Genesys Cloud, new capabilities enable businesses to anticipate individual customer needs, building on every interaction across multiple channels and events to improve and personalize future engagements.PexipAdaptive Composition, an AI-powered technology with real-time face detection, auto-framing and optimized use of screen real estate; works with any camera-enabled device.Theta LakeCompliant Collaboration Archive, new module within Theta Lake’s Compliance Suite for record keeping, archiving and eDiscovery requirements for video, audio and collaboration chat, with on-demand compliance risk analysis using AI and ML across leading UCaaS platforms (RingCentral, WebEx, Microsoft Teams, Zoom, LogMeIn, Red Box).Best Innovation for Advancing Employee/End User EngagementEmbrava (Winner)Embrava Desk Sign, a smart sensor IoT device designed for Hot Desking, Office Hoteling and Activity-Based Working.Mio (Runner-up)Mio’s new intercompany federation for Microsoft Teams, Slack and WebEx Teams, enables users to seamlessly chat with their external business contacts who use a different messaging app.Best of Enterprise Connect judges for 2020 included: Jon Arnold, principal, J Arnold & Associates; Brent Kelly, president & principal analyst, KelCor; Steve Leaden, president, Leaden Associates and Sheila McGee-Smith, founder & principal analyst, McGee-Smith Analytics.Enterprise Connect 2020 will take place August 3rd– 6th at the Moscone Center in San Francisco. For more information on #E20 and to register for the event, go to www.enterpriseconnect.com/sanfrancisco.About Enterprise Connect
For 30 years, Enterprise Connect has been the leading conference and exhibition for enterprise Unified Communications and Collaboration in North America. Enterprise Connect brings corporate IT decision makers together with the industry’s vendors, analysts and consultants to focus on the issues central to enterprise networks and communications. Enterprise Connect owns and produces No Jitter, (nojitter.com), providing daily blogging and analysis of enterprise communications, and it also serves the community with a weekly email newsletter, research surveys and a Webinar Series. For more information, visit enterpriseconnect.com/sanfrancisco. Enterprise Connect is brought to you by Informa Tech.About Informa Tech
Informa Tech is a market leading provider of integrated research, media, training and events to the global Technology community. We’re an international business of more than 600 colleagues, operating in more than 20 markets. Our aim is to inspire the Technology community to design, build and run a better digital world through research, media, training and event brands that inform, educate and connect. Over 7,000 professionals subscribe to our research, with 225,000 delegates attending our events and over 18,000 students participating in our training programs each year, and nearly 4 million people visiting our digital communities each month. Learn more about Informa Tech.Media Contact:
Cancer Biomarker Sales to Reach US$ 27 Bn by 2025; Government Funding Pivotal in Accelerating Market Growth, Says a New Fact.MR Report
Dubai, UAE, April 01, 2020 (GLOBE NEWSWIRE) — The global cancer biomarker market will reach a valuation of US$ 27 Bn by the end of 2025, as projected by a new Fact.MR report. The growth is primarily driven by the increasing prevalence of cancer and the subsequent investments in research and development activities. Factors further complementing the growth are favorable government funding initiatives on cancer diagnostics.Cancer Biomarker Market: Key FindingsCirculating Tumor Test (CTT) and Prostate Specific Antigen (PSA) test collectively account for more than half of overall market value.On the back of high cigarette smoking, lung cancer is expected to be the most common type of cancer, thereby accounting for a quarter total market share in testing.North America is set to account for a large portion of the overall global revenue, on the back of heavy budget allocation by the government for cancer research and training.Asia-Pacific will witness tremendous growth owing to the increasing affordability of cancer treatments in emerging economies.Request Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=4587Cancer Biomarker Market: Key Driving FactorsGovernments in developed and emerging economies are financing clinical trials, thus enabling companies to develop effective diagnostics and treatments for cancer diseases, thus giving a significant boost to the global cancer biomarker market.Invigorated by technological advancements, numerous companies in the diagnostic imaging market are developing advanced, efficient, and economical equipment, and hence, are gaining traction among end-users.Explore the complete cancer biomarkers market report with detailed market segmentation, 64 illustrative figures, and 18 data tables at –
https://www.factmr.com/report/4587/cancer-biomarkers-marketCancer Biomarker Market: Key RestraintMajor factors possessing a challenge to the rapid growth of the market are reluctance among end-users to adopt new technologies and the high cost of biomarker techniques.Competition LandscapeSome of the key players in the global cancer biomarker market are F. Hoffmann-La Roche Ltd., Abbott Technologies & Merck & Co., Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Illumina, Inc., bioMérieux SA, Hologic, Inc., Genomic Health, Inc., and QIAGEN, among others. The market players are adopting Artificial Intelligence (to) to develop their offerings and to decode the cancer pathology.About the ReportThis 170-page study offers a detailed market forecast on the cancer biomarker market. The key categories covered in the report include Market statistics have been presented on the basis of Test Type (PSA tests, CTC tests, AFP tests, CA tests, HER2 tests, BRCA tests, ALK tests, CEA tests, EFGR mutation tests, KRAS mutation tests, and Others) and Disease Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, etc.) across five major regions.Explore Fact.MR’s lucid coverage of the healthcare landscapeAutomated External Defibrillators Market– The automated external defibrillators market study analyses the key trends, innovations, regulatory policies, and key strategies adopted by leading players in this evolving landscape.Atopic Dermatitis Market– The study analyses the atopic dermatitis market and offers growth opportunities in USD million across 30+ countries in six regions.Rare Neurological Disease Treatment Market– With strong growth through 2028, the rare neurological disease market is witnessing substantial growth in a market.About Fact.MRExpert analysis, actionable insights, and strategic recommendations of the highly seasoned research team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the Healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR’s latest healthcare market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.Contact:Fact.MR11140 Rockville PikeSuite 400Rockville, MD 20852United StatesEmail: email@example.comWeb: https://www.factmr.com/PR- https://www.factmr.com/media-release/1360/global-cancer-biomarkers-market
Latest News9 months ago
Bleckwen Raises $10m and Appoints David Christie as CEO
Artificial Intelligence11 months ago
Kneron Debuts Edge AI Chip, Bringing AI to Devices Everywhere
Artificial Intelligence12 months ago
Chartis Research Names FICO a Category Leader in AI for Financial Services
Artificial Intelligence10 months ago
LogRhythm Scores the Singapore Business Review Technology Excellence Award 2019 for Cyber Security – Computer Software
Artificial Intelligence12 months ago
CredoLab extends smartphone-based scoring to insurers
Artificial Intelligence12 months ago
Tuya Exhibiting Products from its Global Clients that are “Powered by Tuya”
Artificial Intelligence10 months ago
Chengdu Tianfu Software Park Reflects the Vitality of IP Innovation
Artificial Intelligence6 months ago
Mogo announces a digital lending pilot with goeasy Ltd.